Eficacia y seguridad de vareniclina en el abandono del tabaquismo

Banegas, 2011, Mortalidad atribuible al consumo de tabaco en España en 2006, Med Clin (Barc), 136, 97, 10.1016/j.medcli.2010.03.039 Shearer, 2006, Cost effectiveness analysis of smoking cessation interventions, Aust N Z J Public Health, 30, 428, 10.1111/j.1467-842X.2006.tb00458.x Eddy, 1992, Davis Eddy ranks the tests, Harv Health Lett, 10 Coe, 2005, Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation, J Med Chem, 48, 3474, 10.1021/jm050069n Silagy, 2004, Nicotine replacement therapy for smoking cessation, Cochrane Database Syst Rev, 10.1002/14651858.CD000146.pub2 Hughes, 2007, Antidepressants for smoking cessation, Cochrane Database Syst Rev, 10.1002/14651858.CD000031.pub3 Gonzales, 2006, Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs. sustained- release bupropion and placebo for smoking cessation: a randomized controlled trial, JAMA., 296, 47, 10.1001/jama.296.1.47 Cahill, 2007, Nicotine receptor partial agonists for smoking cessation, Cochrane Database Syst Rev, 10.1002/14651858.CD006103.pub2 Jorenby, 2006, Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial, JAMA, 296, 56, 10.1001/jama.296.1.56 Fiore, 2008, Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline Jarvis, 1980, Expired air carbon monoxide: a simple breath test of tobacco smoke intake, Br Med J, 281, 484, 10.1136/bmj.281.6238.484 Jiménez Ruiz, 2001, Grupo de Trabajo del Área de Tabaquismo de la SEPAR. Recomendaciones para la organización y funcionamiento de las unidades especializadas en tabaquismo, Arch Bronconeumol, 37, 382, 10.1016/S0300-2896(01)78819-9 Alonso Muñoz, 2007, 9 Jiménez Ruiz, 2003, Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. Documento de consenso, Arch Bronconeumol, 39, 35, 10.1016/S0300-2896(03)75312-5 Nides, 2006, Smoking cessation with varenicline, a selective a4b2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up, Arch Intern Med, 166, 1561, 10.1001/archinte.166.15.1561 Oncken, 2006, Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation, Arch Intern Med, 166, 1571, 10.1001/archinte.166.15.1571 Jiménez Ruiz, 2008, Eficacia y seguridad de vareniclina en la práctica clínica, Rev Pat Respir, 11, 151 Tonstad, 2006, Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial, JAMA, 296, 64, 10.1001/jama.296.1.64 Williams, 2007, A double-blind study evaluating the long-term safety of varenicline for smoking cessation, Curr Med Res Opin, 23, 793, 10.1185/030079907X182185 Rigotti, 2010, Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial, Circulation, 121, 221, 10.1161/CIRCULATIONAHA.109.869008 Tashkin, 2011, Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial, 139, 591